We are live on ! Find out more
RADX

Radiopharm Theranostics
RADX

4 hedge funds and large institutions have $1.94M invested in Radiopharm Theranostics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
4
Holders Change
+4
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
+$1.23M
2
AAA
Affinity Asset Advisors
New York
+$1.03M
3
RP
Regal Partners
Australia
+$598K
4
UBS Group
UBS Group
Switzerland
+$8.66K

Top Sellers

No sellers this quarter

RADX Hedge Fund Activity: Q4 2024 in Review

4 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q4 2024, worth a combined $1.94M.

Buyers outnumbered sellers: 4 funds opened new RADX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $1.23M.

  • 4 institutional investors held Radiopharm Theranostics (RADX) as of Q4 2024, up from 0 in Q3 2024.
  • Funds reported $1.94M of Radiopharm Theranostics stock for Q4 2024.
  • 4 funds opened new Radiopharm Theranostics positions in Q4 2024 and 0 closed out, a net change of +4 holders.
  • The largest Radiopharm Theranostics buyer in Q4 2024 was Silverarc Capital Management, an estimated $1.23M added.

Based on aggregated 13F filings for Q4 2024.